Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

By G. Targher, C. Day, E. Bonora. New England Journal of Medicine, 2010

1,751 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/590d7084f2176d449028452649ff4300387b3441

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Hepatology

Citations in the corpus

ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (2011, background): “NASH can progress to cirrhosis(4) and is also associated with an increased risk of cardiovascular mortality and type 2 diabetes mellitus.(5,6) Cirrhosis due to NASH increases the risk of hepatocellular carcinoma and NASH contributes substantially to the population burden of hepatocellular cancer.”
NAFLD: a multisystem disease. (2015, background): “It is likely that there is a pathogenic ‘‘cross-talk’’ between the liver and the expanded and ‘dysfunctional’ (inflamed) adipose tissue [1,18,58,72,75].”
Non-Alcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases (2017, positive): “Unsurprisingly, NAFLD is a risk factor for many metabolic diseases, including T2D (Lallukka and Yki-J€arvinen, 2016) and cardiovascular dis- ease (Targher et al., 2010).”
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up (2015, background): “NASH is considered the more aggressive part of the NAFLD spectrum, associated with progressive fibrosis as well as higher risk of cardiovascular disease.(7,8) Today, NAFLD is the third most common cause for need of liver transplantation, and on the trajectory of becoming the most common cause.”
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “9 10 However, the nature and extent of the associations between NAFLD and CVD is not clear.”
Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics (2017, background): “…b cells, retinal pigment epithelium (RPE), and even skeletal muscle (Adijanto et al., 2014; Avogaro et al., 1992; El Azzouny et al., 2016; Grabacka et al., 2016; Kang et al., 2015; Le Foll et al., 2014; Nonaka et al., 2016; Takagi et al., 2016a; Thevenet et al., 2016; Zhang et al., 2011).”
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “Statin use in patients with NAFLD and NASH Patients with NAFLD and NASH are at increased risk for cardiovascular disease and several studies have established cardiovascular disease as their most common cause of death.(6) Patients with NAFLD should be risk stratified for cardiovascular disease, and t”
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss (2022, background): “Studies have shown the increased prevalence of cardiovascular disease (CVD) in patients with NAFLD, without and without diabetes [18, 19].”